Introduction
Phyllodes tumor and fibroadenoma are two types of biphasic tumors of the breast. They are composed of various combinations of proliferating epithelial and stromal elements. I ,4 Phyllodes tumor (PT) is a rare fibroepithelial neoplasm of the breast that account for 0.3% to 1.5% of breast tumors in females and approximately 2.5% of all fibroepithelial breast tumors. 5 Fibroadenoma (FA) is the most common benign tumor that causes breast masses in young women.
3 Generally PT occur in an older age group than fibroadenomas; most patients are middle aged or elderly.
2 Phyllodes tumors are classified as benign, borderline or malignant on the basis of stromal cellularity, nuclear atypia, mitotic activity, stromal overgowth and type of border (infiltrating or pushing) .12 Histopathologically, PT (PT) is composed of a benign epithelial component and a cellular spindle cell stroma; the stroma is characterised by formation of leaf-like processes protruding into cystic spaces. 5 Benign PT is generally used as a synonym of fibroadenoma phyllodes where the cellularity of the stroma is similar to fibroadenoma, but the leaf-like processes are readily identifiable. I There is a distinct difference in the clinical course between FA and borderline/malignant PT. Clinically most PTs tend to behave in a benign fashion, but, unlike FA, tlley cml recur locally (in 16-30%)5 and can undergo malignant progression to sarcoma.
ll , 12 In many instances, differential diagnosis of FA and BPT poses no difficulty but in complicated cases such as FA with a slightly higher cellular stroma or with focal phyllodes structure differential diagnosis is problematic. 13 However, in general, tlle stromal cell cellularity in PT is higher than in FA, and the nuclear atypia of the former is more prominent than the latter. 3 The histogenesis of PT and tllat of FA of the breast appears to be closely related " IJ' ., and discrimination between them by histopathological analysis is sometimes problematic.~, 14 There is no histologic feature that will always provide an absolute and universally accepted distinction between the two lesions. 2 The aim of this study is to find out whether the immonohistochemical assessment of proliferative activity using Ki-67 antigen and proliferating cell nuclear antigen (PCNA) can help to differentiate BPT from cellular FA.
Materials and Methods

Patients and tissues
Thirtyone benign PT and 12 cellular FA were retrieved from the archives of Pathology Department of Akdeniz University, School of Medicine. According to mentioned criteria all of PT were benign that had similar stromal cellularity with fibroadenomas but identifiable leaf-like processes (Figure 1 ). The designation of cellular FA was used if the tumor lacked or had rare and poorly formed leaf-like processes and the stroma showed minimally increased cellularity (Figure~.I All of FA cases were cellular. Mean age of PT patients and FA patients were 32.6 years (range: 19-45) and 24.3 years (range: 14-36) respectively. Median tumor size of BPT patients and FA patients were 2.5 cm (range: 1-5) and 2.5 cm (range: 1.5-12). The tumor sizes of three FA patients were 6, 7 and 12 cm which were defined as giant fibroadenomas (4 cm and larger).6
Immunostaining
For immunohistochemical analysis, 4-5J1m thick sections of paraffin blocks of FA and PT cases were rehydrated according to standard protocol. Sections were immunostained in automated immunohistochemistry system (Techmate 500, DAKO, Denmark) by streptavidin biotin peroxidase protocol. Primary antibodies were PCNA (diluted at 1:50, monoclonal, PClo, DAKO, Denmark) and Ki-67 antigen (diluted at 1:50, monoclonal Ki-S5, DAKO, Denmark). In each group proliferating activity of epithelial and stromal cells were evaluated. Positive stained percent of nuclei were assessed as labeling index (LI) by counting at least 500 cells at high power (x400). The fields with the highest cellular area within the tumor were selected for cell counting.
Statistical analysis
Statistics between FA and PT groups were performed by Mann-Whitney U test and parameters were compared by correlation tests in each group. P values :0::0.05 were regarded significant.
Results
We retrospectively examined 31 benign PT and 12 cellular FA. The average values of age, tumor size, LI of PCNA and Ki-67 antigen (%) are summarized in Table 1 . FA patients were younger than BPT patients (p=0.008). PCNA LI in epithelial and stromal components demonstrated a positive correlation overall (Figure 3 ) (r=0.55, p=O.OOOl) and inside FA group (r=0.64, p=0.025). There was not statistically significant difference in tumor sizes between PT and FA. Figure 4 shows tile PCNA positivity in PT. In both groups, there were not any correlation with the diameter of tumors and proliferative activity. There was no significant difference between the proliferating activity of BPT and cellular fibroadenomas.
Discussion
Phyllodes tumor of the breast is well-known for its unpredictable behavior in terms of local recurrences and distant metastases. There is now a clear consensus that histopathological appearence and biological behavior in PT of the breast may poorly correlate, and histopathological features '3 In our study, we defined FA with phyllodes structure as a benign PT and we also did not find any statistically significant difference in the proliferative activity of cellular FA anfbenign phyllodes tumor. Kocova et al found that there was a statistically significant difference in MIB 1 indices of benign PT and FA" The histopathologic criteria used in this study differed from the criteria of current study. We used the histopathologic criteria designated by alone are of relatively limited value in discriminating benign and malignant PT." Recently the determination of proliferative activity has given additional information on the biological behavior and clinical outcome of different neoplasms."'!" Proliferative activity can be determined by two different immunohistochemical marker, Ki-67 and PCNA. Ki-67 (MIB 1) is a non-histone nuclear protein that is present through the whole cell cycle.
lO However some investigators observe that Ki-67 reaches the peak value during the G2/M phase of the cell cycle.
7 On the other hand PCNA is also a non-histone nuclear protein and is present in the late G1 phase, with the peak in GliS interphase of the cell cycle. Iavassoli et a1. in AFIP. 1 In the current study, though we used two different proliferative markers, we did not find any significant difference between benign PI and cellular FA. As we had no malignant or borderline PI, no comparison could be made between benign mnd malignant PIs.
We concluded tl1at determination of the proliferating activity of benign PI and cellular FA did not help to differentiate these neoplasms.
